Drug Patents owned by Anacor Pharms Inc
1. Drug name - EUCRISA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(6 years from now) | |
| CN101160124A | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Apr, 2011
(11 years ago) | |
| CN101505603A | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Jul, 2012
(10 years ago) | |
| CN101914109A | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Feb, 2026
(3 years from now) | |
| CN102532180A | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Feb, 2026
(3 years from now) | |
| CN102532180B | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Feb, 2026
(3 years from now) | |
| CN101914109B | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Feb, 2026
(3 years from now) | |
| IN200701176P3 | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Feb, 2026
(3 years from now) | |
| IN265043B | ANACOR PHARMS INC | A Pharmaceutical Formulation Of Boron-Containing Small Molecules For Topical Application |
Feb, 2026
(3 years from now) | |
| EP3424932B1 | ANACOR PHARMS INC | Boronophthalides For Therapeutic Use |
Feb, 2026
(3 years from now) | |
| EP2987796A1 | ANACOR PHARMS INC | Halogen-Substituted Boronophthalides For The Treatment Of Infections |
Feb, 2026
(3 years from now) | |
| EP1853251A2 | ANACOR PHARMS INC | Halogen-Substituted Boronophthalides For The Treatment Of Infections |
Feb, 2026
(3 years from now) | |
| EP2987796B1 | ANACOR PHARMS INC | Halogen-Substituted Boronophthalides For The Treatment Of Infections |
Feb, 2026
(3 years from now) | |
| EP3424932A1 | ANACOR PHARMS INC | Boronophthalides For Therapeutic Use |
Feb, 2026
(3 years from now) | |
| EP1853251A4 | ANACOR PHARMS INC | Boron-Containing Small Molecules |
Feb, 2026
(3 years from now) | |
| EP1853251B1 | ANACOR PHARMS INC | Halogen-Substituted Boronophthalides For The Treatment Of Infections |
Feb, 2026
(3 years from now) | |
| EP2343304A1 | ANACOR PHARMS INC | Biocidal Boronophthalide Compounds |
Feb, 2026
(3 years from now) | |
| EP2343304B1 | ANACOR PHARMS INC | Biocidal Boronophthalide Compounds |
Feb, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(4 years from now) | |
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(4 years from now) | |
|
US9682092
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(4 years from now) | |
|
US8501712
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(4 years from now) | |
|
US8039451
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(7 years from now) | |
| US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(7 years from now) | |
|
US8168614
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(7 years from now) | |
Drugs and Companies using CRISABOROLE ingredient
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2% | OINTMENT;TOPICAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.